Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2500
Single User License Price INR 168625
Corporate User License Price USD 7500
Corporate User License Price INR 505875
Site License Price USD 5000
Site License Price INR 337250
Request a Quote

Report Title

Head And Neck Cancer-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2500
Site License USD 5000
Enterprise Wide License USD 7500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Head And Neck Cancer-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Head And Neck Cancer-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Head And Neck Cancer-Pipeline Review, H1 2017



Executive Summary

Head And Neck Cancer-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer-Pipeline Review, H1 2017, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 87, 98, 5, 92, 17 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 6, 1, 15 and 3 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 9

Head And Neck Cancer-Overview 10

Head And Neck Cancer-Therapeutics Development 11

Head And Neck Cancer-Therapeutics Assessment 51

Head And Neck Cancer-Companies Involved in Therapeutics Development 75

Head And Neck Cancer-Drug Profiles 167

Head And Neck Cancer-Dormant Projects 1190

Head And Neck Cancer-Discontinued Products 1200

Head And Neck Cancer-Product Development Milestones 1202

Appendix 1211

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Head And Neck Cancer, H1 2017 46

Number of Products under Development by Companies, H1 2017 47

Number of Products under Development by Universities/Institutes, H1 2017 60

Number of Products by Top 10 Targets, H1 2017 86

Number of Products by Stage and Top 10 Targets, H1 2017 86

Number of Products by Top 10 Mechanism of Actions, H1 2017 96

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 96

Number of Products by Top 10 Routes of Administration, H1 2017 106

Number of Products by Stage and Top 10 Routes of Administration, H1 2017 106

Number of Products by Top 10 Molecule Types, H1 2017 108

Number of Products by Stage and Top 10 Molecule Types, H1 2017 108

List of Tables

Number of Products under Development for Head And Neck Cancer, H1 2017 46

Number of Products under Development by Companies, H1 2017 48

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 49

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 50

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 51

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 52

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 53

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 54

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 55

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 56

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 57

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 58

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 59

Number of Products under Development by Universities/Institutes, H1 2017 60

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 62

Products under Development by Companies, H1 2017 63

Products under Development by Companies, H1 2017 (Contd..1), H1 2017 64

Products under Development by Companies, H1 2017 (Contd..2), H1 2017 65

Products under Development by Companies, H1 2017 (Contd..3), H1 2017 66

Products under Development by Companies, H1 2017 (Contd..4), H1 2017 67

Products under Development by Companies, H1 2017 (Contd..5), H1 2017 68

Products under Development by Companies, H1 2017 (Contd..6), H1 2017 69

Products under Development by Companies, H1 2017 (Contd..7), H1 2017 70

Products under Development by Companies, H1 2017 (Contd..8), H1 2017 71

Products under Development by Companies, H1 2017 (Contd..9), H1 2017 72

Products under Development by Companies, H1 2017 (Contd..10), H1 2017 73

Products under Development by Companies, H1 2017 (Contd..11), H1 2017 74

Products under Development by Companies, H1 2017 (Contd..12), H1 2017 75

Products under Development by Companies, H1 2017 (Contd..13), H1 2017 76

Products under Development by Companies, H1 2017 (Contd..14), H1 2017 77

Products under Development by Companies, H1 2017 (Contd..15), H1 2017 78

Products under Development by Companies, H1 2017 (Contd..16), H1 2017 79

Products under Development by Companies, H1 2017 (Contd..17), H1 2017 80

Products under Development by Companies, H1 2017 (Contd..18), H1 2017 81

Products under Development by Companies, H1 2017 (Contd..19), H1 2017 82

Products under Development by Universities/Institutes, H1 2017 83

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 84

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 85

Number of Products by Stage and Target, H1 2017 87

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 88

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 89

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 90

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 91

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 92

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 93

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 94

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017 95

Number of Products by Stage and Mechanism of Action, H1 2017 97

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 98

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 99

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 100

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 101

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 102

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 103

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 104

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017 105

Number of Products by Stage and Route of Administration, H1 2017 107

Number of Products by Stage and Molecule Type, H1 2017 109

Head And Neck Cancer-Pipeline by 3SBio Inc, H1 2017 110

Head And Neck Cancer-Pipeline by 4SC AG, H1 2017 110

Head And Neck Cancer-Pipeline by AB Science SA, H1 2017 111

Head And Neck Cancer-Pipeline by AbbVie Inc, H1 2017 111

Head And Neck Cancer-Pipeline by Abion Inc, H1 2017 112

Head And Neck Cancer-Pipeline by Accelerated Pharma Inc, H1 2017 112

Head And Neck Cancer-Pipeline by Acceleron Pharma Inc, H1 2017 113

Head And Neck Cancer-Pipeline by Adaptimmune Therapeutics Plc, H1 2017 113

Head And Neck Cancer-Pipeline by Aduro BioTech Inc, H1 2017 114

Head And Neck Cancer-Pipeline by Advaxis Inc, H1 2017 114

Head And Neck Cancer-Pipeline by Advenchen Laboratories LLC, H1 2017 115

Head And Neck Cancer-Pipeline by Affimed GmbH, H1 2017 115

Head And Neck Cancer-Pipeline by Altor BioScience Corp, H1 2017 116

Head And Neck Cancer-Pipeline by Ambrx Inc, H1 2017 116

Head And Neck Cancer-Pipeline by amcure GmbH, H1 2017 117

Head And Neck Cancer-Pipeline by Amgen Inc, H1 2017 117

Head And Neck Cancer-Pipeline by arGEN-X BV, H1 2017 118

Head And Neck Cancer-Pipeline by ArQule Inc, H1 2017 118

Head And Neck Cancer-Pipeline by Array BioPharma Inc, H1 2017 119

Head And Neck Cancer-Pipeline by Aspyrian Therapeutics Inc, H1 2017 119

Head And Neck Cancer-Pipeline by Astellas Pharma Inc, H1 2017 120

Head And Neck Cancer-Pipeline by AstraZeneca Plc, H1 2017 121

Head And Neck Cancer-Pipeline by Atara Biotherapeutics Inc, H1 2017 122

Head And Neck Cancer-Pipeline by ATLAB Pharma SAS, H1 2017 122

Head And Neck Cancer-Pipeline by AVEO Pharmaceuticals Inc, H1 2017 123

Head And Neck Cancer-Pipeline by Bayer AG, H1 2017 124

Head And Neck Cancer-Pipeline by BeiGene Ltd, H1 2017 124

Head And Neck Cancer-Pipeline by Benitec Biopharma Ltd, H1 2017 125

Head And Neck Cancer-Pipeline by Beta Pharma Inc, H1 2017 125

Head And Neck Cancer-Pipeline by Bexion Pharmaceuticals LLC, H1 2017 126

Head And Neck Cancer-Pipeline by BioDiem Ltd, H1 2017 126

Head And Neck Cancer-Pipeline by Biomics Biotechnologies Co Ltd, H1 2017 127

Head And Neck Cancer-Pipeline by Bionovis SA, H1 2017 127

Head And Neck Cancer-Pipeline by BioNTech AG, H1 2017 128

Head And Neck Cancer-Pipeline by Biotest AG, H1 2017 128

Head And Neck Cancer-Pipeline by Biothera Pharmaceutical Inc, H1 2017 129

Head And Neck Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2017 129

Head And Neck Cancer-Pipeline by Boston Biomedical Inc, H1 2017 130

Head And Neck Cancer-Pipeline by Bristol-Myers Squibb Company, H1 2017 130

Head And Neck Cancer-Pipeline by CBT Pharmaceuticals Inc, H1 2017 131

Head And Neck Cancer-Pipeline by Celgene Corp, H1 2017 131

Head And Neck Cancer-Pipeline by Cell Medica Ltd, H1 2017 132

Head And Neck Cancer-Pipeline by Cellceutix Corp, H1 2017 132

Head And Neck Cancer-Pipeline by Celldex Therapeutics Inc, H1 2017 133

Head And Neck Cancer-Pipeline by Celprogen Inc, H1 2017 133

Head And Neck Cancer-Pipeline by Centrose LLC, H1 2017 134

Head And Neck Cancer-Pipeline by Corvus Pharmaceuticals Inc, H1 2017 134

Head And Neck Cancer-Pipeline by Cristal Therapeutics BV, H1 2017 135

Head And Neck Cancer-Pipeline by Critical Outcome Technologies Inc, H1 2017 135

Head And Neck Cancer-Pipeline by CytImmune Sciences Inc, H1 2017 136

Head And Neck Cancer-Pipeline by Daiichi Sankyo Company Ltd, H1 2017 136

Head And Neck Cancer-Pipeline by Denceptor Therapeutics Ltd, H1 2017 137

Head And Neck Cancer-Pipeline by DNJ Pharma Inc, H1 2017 137

Head And Neck Cancer-Pipeline by Dynavax Technologies Corp, H1 2017 138

Head And Neck Cancer-Pipeline by Eisai Co Ltd, H1 2017 138

Head And Neck Cancer-Pipeline by Eleven Biotherapeutics Inc, H1 2017 139

Head And Neck Cancer-Pipeline by Eli Lilly and Company, H1 2017 139

Head And Neck Cancer-Pipeline by Etubics Corp, H1 2017 140

Head And Neck Cancer-Pipeline by Eureka Therapeutics Inc, H1 2017 140

Head And Neck Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 141

Head And Neck Cancer-Pipeline by Five Prime Therapeutics Inc, H1 2017 141

Head And Neck Cancer-Pipeline by Forty Seven Inc, H1 2017 142

Head And Neck Cancer-Pipeline by Fujifilm Corp, H1 2017 142

Head And Neck Cancer-Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017 143

Head And Neck Cancer-Pipeline by Galectin Therapeutics Inc, H1 2017 143

Head And Neck Cancer-Pipeline by Genelux Corp, H1 2017 144

Head And Neck Cancer-Pipeline by GeneSegues Inc, H1 2017 144

Head And Neck Cancer-Pipeline by Genexine Inc, H1 2017 145

Head And Neck Cancer-Pipeline by Genmab A/S, H1 2017 145

Head And Neck Cancer-Pipeline by GlaxoSmithKline Plc, H1 2017 146

Head And Neck Cancer-Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017 147

Head And Neck Cancer-Pipeline by Gliknik Inc, H1 2017 147

Head And Neck Cancer-Pipeline by Glycotope GmbH, H1 2017 148

Head And Neck Cancer-Pipeline by Griffith University, H1 2017 148

Head And Neck Cancer-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 149

Head And Neck Cancer-Pipeline by Hookipa Biotech AG, H1 2017 149

Head And Neck Cancer-Pipeline by Horizon Pharma Plc, H1 2017 150

Head And Neck Cancer-Pipeline by Hutchison China MediTech Ltd, H1 2017 150

Head And Neck Cancer-Pipeline by Ignyta Inc, H1 2017 151

Head And Neck Cancer-Pipeline by Immunocore Ltd, H1 2017 151

Head And Neck Cancer-Pipeline by Immunomedics Inc, H1 2017 152

Head And Neck Cancer-Pipeline by Immunovaccine Inc, H1 2017 152

Head And Neck Cancer-Pipeline by Immunovative Therapies Ltd, H1 2017 153

Head And Neck Cancer-Pipeline by Incyte Corp, H1 2017 153

Head And Neck Cancer-Pipeline by Infinity Pharmaceuticals Inc, H1 2017 154

Head And Neck Cancer-Pipeline by Innate Pharma SA, H1 2017 154

Head And Neck Cancer-Pipeline by Inovio Pharmaceuticals Inc, H1 2017 155

Head And Neck Cancer-Pipeline by InteRNA Technologies BV, H1 2017 155

Head And Neck Cancer-Pipeline by Ipsen SA, H1 2017 156

Head And Neck Cancer-Pipeline by IRX Therapeutics Inc, H1 2017 156

Head And Neck Cancer-Pipeline by ISA Pharmaceuticals BV, H1 2017 157

Head And Neck Cancer-Pipeline by ISU ABXIS Co Ltd, H1 2017 157

Head And Neck Cancer-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 158

Head And Neck Cancer-Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017 158

Head And Neck Cancer-Pipeline by Johnson & Johnson, H1 2017 159

Head And Neck Cancer-Pipeline by Juno Therapeutics Inc, H1 2017 159

Head And Neck Cancer-Pipeline by Kite Pharma Inc, H1 2017 160

Head And Neck Cancer-Pipeline by Kura Oncology Inc, H1 2017 160

Head And Neck Cancer-Pipeline by Laboratoires Pierre Fabre SA, H1 2017 161

Head And Neck Cancer-Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017 161

Head And Neck Cancer-Pipeline by Lion Biotechnologies Inc, H1 2017 162

Head And Neck Cancer-Pipeline by Loxo Oncology Inc, H1 2017 162

Head And Neck Cancer-Pipeline by Lytix Biopharma AS, H1 2017 163

Head And Neck Cancer-Pipeline by Mabion SA, H1 2017 163

Head And Neck Cancer-Pipeline by MacroGenics Inc, H1 2017 164

Head And Neck Cancer-Pipeline by Marsala Biotech Inc, H1 2017 164

Head And Neck Cancer-Pipeline by Mateon Therapeutics Inc, H1 2017 165

Head And Neck Cancer-Pipeline by MaxiVAX SA, H1 2017 165

Head And Neck Cancer-Pipeline by Meabco A/S, H1 2017 166

Head And Neck Cancer-Pipeline by MedImmune LLC, H1 2017 167

Head And Neck Cancer-Pipeline by Merck & Co Inc, H1 2017 168

Head And Neck Cancer-Pipeline by Merck KGaA, H1 2017 169

Head And Neck Cancer-Pipeline by Millennium Pharmaceuticals Inc, H1 2017 169

Head And Neck Cancer-Pipeline by Mirati Therapeutics Inc, H1 2017 170

Head And Neck Cancer-Pipeline by Moleculin Biotech Inc, H1 2017 170

Head And Neck Cancer-Pipeline by Molplex Ltd, H1 2017 171

Head And Neck Cancer-Pipeline by NanoCarrier Co Ltd, H1 2017 171

Head And Neck Cancer-Pipeline by NantKwest Inc, H1 2017 172

Head And Neck Cancer-Pipeline by Natco Pharma Ltd, H1 2017 172

Head And Neck Cancer-Pipeline by NeoImmuneTech Inc, H1 2017 173

Head And Neck Cancer-Pipeline by Neonc Technologies Inc, H1 2017 173

Head And Neck Cancer-Pipeline by Neumedicines Inc, H1 2017 174

Head And Neck Cancer-Pipeline by Northwest Biotherapeutics Inc, H1 2017 174

Head And Neck Cancer-Pipeline by Novartis AG, H1 2017 175

Head And Neck Cancer-Pipeline by Noxopharm Ltd, H1 2017 175

Head And Neck Cancer-Pipeline by Oncobiologics Inc, H1 2017 176

Head And Neck Cancer-Pipeline by Oncolys BioPharma Inc, H1 2017 176

Head And Neck Cancer-Pipeline by Onconova Therapeutics Inc, H1 2017 177

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

3SBio Inc, 4SC AG, AB Science SA, AbbVie Inc, Abion Inc, Accelerated Pharma Inc, Acceleron Pharma Inc, Adaptimmune Therapeutics Plc, Aduro BioTech Inc, Advaxis Inc, Advenchen Laboratories LLC, Affimed GmbH, Altor BioScience Corp, Ambrx Inc, amcure GmbH, Amgen Inc, arGEN-X BV, ArQule Inc, Array BioPharma Inc, Aspyrian Therapeutics Inc, Astellas Pharma Inc, AstraZeneca Plc, Atara Biotherapeutics Inc, ATLAB Pharma SAS, AVEO Pharmaceuticals Inc, Bayer AG, BeiGene Ltd, Benitec Biopharma Ltd, Beta Pharma Inc, Bexion Pharmaceuticals LLC, BioDiem Ltd, Biomics Biotechnologies Co Ltd, Bionovis SA, BioNTech AG, Biotest AG, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, CBT Pharmaceuticals Inc, Celgene Corp, Cell Medica Ltd, Cellceutix Corp, Celldex Therapeutics Inc, Celprogen Inc, Centrose LLC, Corvus Pharmaceuticals Inc, Cristal Therapeutics BV, Critical Outcome Technologies Inc, CytImmune Sciences Inc, Daiichi Sankyo Company Ltd, Denceptor Therapeutics Ltd, DNJ Pharma Inc, Dynavax Technologies Corp, Eisai Co Ltd, Eleven Biotherapeutics Inc, Eli Lilly and Company, Etubics Corp, Eureka Therapeutics Inc, F. Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Forty Seven Inc, Fujifilm Corp, G&E Herbal Biotechnology Co Ltd, Galectin Therapeutics Inc, Genelux Corp, GeneSegues Inc, Genexine Inc, Genmab A/S, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, Gliknik Inc, Glycotope GmbH, Griffith University, Hanmi Pharmaceuticals Co Ltd, Hookipa Biotech AG, Horizon Pharma Plc, Hutchison China MediTech Ltd, Ignyta Inc, Immunocore Ltd, Immunomedics Inc, Immunovaccine Inc, Immunovative Therapies Ltd, Incyte Corp, Infinity Pharmaceuticals Inc, Innate Pharma SA, Inovio Pharmaceuticals Inc, InteRNA Technologies BV, Ipsen SA, IRX Therapeutics Inc, ISA Pharmaceuticals BV, ISU ABXIS Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, Juno Therapeutics Inc, Kite Pharma Inc, Kura Oncology Inc, Laboratoires Pierre Fabre SA, LATITUDE Pharmaceuticals Inc, Lion Biotechnologies Inc, Loxo Oncology Inc, Lytix Biopharma AS, Mabion SA, MacroGenics Inc, Marsala Biotech Inc, Mateon Therapeutics Inc, MaxiVAX SA, Meabco A/S, MedImmune LLC, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc, Moleculin Biotech Inc, Molplex Ltd, NanoCarrier Co Ltd, NantKwest Inc, Natco Pharma Ltd, NeoImmuneTech Inc, Neonc Technologies Inc, Neumedicines Inc, Northwest Biotherapeutics Inc, Novartis AG, Noxopharm Ltd, Oncobiologics Inc, Oncolys BioPharma Inc, Onconova Therapeutics Inc, OncoSec Medical Inc, Oncovir Inc, Ono Pharmaceutical Co Ltd, Oryx GmbH & Co KG, PCI Biotech Holding ASA, PDS Biotechnology Corp, Pfizer Inc, Pharma Mar SA, Pique Therapeutics, PlantForm Corp, Plexxikon Inc, PNP Therapeutics Inc, Profectus BioSciences Inc, Provectus Biopharmaceuticals Inc, PsiOxus Therapeutics Ltd, R Pharm, Redx Pharma Plc, Reliance Life Sciences Pvt Ltd, Sareum Holdings Plc, Selecta Biosciences Inc, Shionogi & Co Ltd, Sierra Oncology Inc, Sillajen Biotherapeutics, Sinil Pharmaceutical Co Ltd, Sorrento Therapeutics Inc, Sound Pharmaceuticals Inc, SuviCa Inc, Symphogen A/S, SynCore Biotechnology Co Ltd, Taiwan Liposome Company Ltd, Takara Bio Inc, Takis Srl, Tessa Therapeutics Pte Ltd, Theravectys SA, Threshold Pharmaceuticals Inc, Tolero Pharmaceuticals Inc, Transgene SA, UbiVac LLC, Vaccibody AS, VasGene Therapeutics Inc, Vault Pharma Inc, Vaxeal Holding SA, VentiRx Pharmaceuticals Inc, Viracta Therapeutics Inc, Yabao Pharmaceutical Group Co Ltd

Head And Neck Cancer Therapeutic Products under Development, Key Players in Head And Neck Cancer Therapeutics, Head And Neck Cancer Pipeline Overview, Head And Neck Cancer Pipeline, Head And Neck Cancer Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand